By Kelly Cloonan
Eli Lilly expanded its work with Camurus, extending its rights to use one of the Swedish biopharmaceutical firm's technologies to develop and commercialize drugs.
Camurus said Monday that Lilly exercised its option to include amylin receptor agonists in the companies' collaboration and license agreement entered into in June 2025. The move expands Lilly's exclusive rights to Camurus' FluidCrystal technology for the development and commercialization of long-acting cardiometabolic drugs to an additional compound class.
Under the agreement, Camurus is eligible to receive up to $290 million in upfront development and regulatory milestone payments, as well as $580 million in sales-based milestone payments. The company is also eligible to earn tiered mid-single-digit royalties on product sales.
Lilly's move to exercise the extension option triggers a $5 million initial payment to Camurus, is subject to milestone payments and the same royalty levels as other compounds in the collaboration, Camurus said.
FluidCrystal is designed to deliver therapeutic levels of a drug over extended periods, stretching from days to months, with a single injection using a prefilled syringe or autoinjector pen. The technology has commercial and regulatory approvals in Europe, the U.S. and Australia.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
June 01, 2026 12:26 ET (16:26 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.